Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
US5886036 | ABBVIE | Retroviral protease inhibiting compounds |
Nov, 2013
(10 years ago) | |
US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
US5886036 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
May, 2014
(9 years ago) | |
US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
US5914332 | ABBVIE | Retroviral protease inhibiting compounds |
Dec, 2015
(8 years ago) | |
US6284767 | ABBVIE | Retroviral protease inhibiting compounds |
Feb, 2016
(8 years ago) | |
US5914332 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jun, 2016
(7 years ago) | |
US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
US6284767 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Aug, 2016
(7 years ago) | |
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
US6458818 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6521651 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
US6521651 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(6 years ago) | |
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(6 years ago) | |
US6458818 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(6 years ago) | |
US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
US6911214 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
US8501219 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
US6911214 (Pediatric) | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
May, 2022
(1 year, 11 months ago) | |
US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(7 months from now) | |
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
US8309613 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2025
(1 year, 1 month from now) | |
US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
US8377952 | ABBVIE | Solid pharmaceutical dosage formulation |
Oct, 2027
(3 years from now) | |
US8025899 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2027
(3 years from now) | |
US8377952 (Pediatric) | ABBVIE | Solid pharmaceutical dosage formulation |
Apr, 2028
(3 years from now) | |
US8025899 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-124) | Apr 27, 2013 |
Market Authorisation Date: 15 September, 2000
Treatment: Treatment of hiv-infection in combination with other antiretroviral agents; Treatment of hiv infection in combination with other antiretroviral agents; Inhibiting protease with lopinavir and inhibitin...
Dosage: SOLUTION;ORAL; TABLET;ORAL; CAPSULE;ORAL